TOG Review (RCOG Journal)
MRCOG Part 2
Antenatal Care
The role of antenatal corticosteroids in improving neonatal outcomes
Key Statistics
- 24+0–33+6 weeks — Single-course ACS window (WHO/NICE/ACOG)
- 0.66 — RR RDS, ACS vs none (Cochrane, 30 trials)
- 18–36h — Optimal ACS-to-delivery interval for max benefit
Don't-miss facts
-
ACS benefit is time-limited: only clear benefit if delivery occurs within 7 days of administration – accurate prediction of preterm birth risk is essential
-
Standard course: betamethasone 12 mg IM ×2, 24h apart OR dexamethasone 6 mg IM ×4, 12h apart; single course 24+0–33+6 weeks (WHO/NICE/ACOG)
-
Greatest mortality benefit if given 18–36 hours pre-delivery; >7 days before delivery linked to a 40% relative ↑ in mortality vs the 1–7 day window
-
NICE: do not routinely repeat ACS courses; ACOG/WHO allow a single rescue course if still high risk and ≥7–14 days from last course
-
Repeat ACS courses consistently ↓birthweight/growth (ACTORDS, MACS, NICHD); MACS 5-year data show repeat- exposed infants born at term have ↑death/disability (OR 1.69) and ↑neurosensory disability (OR 3.70)
-
ALPS trial (late preterm 34+0–36+5 weeks): ACS ↓respiratory morbidity but ↑neonatal hypoglycaemia (24.0% vs 15.0%)
-
ACT trial in LMIC: ACS associated with ↑28-day mortality (RR 1.12) in the whole study population – high-income evidence of benefit does not automatically apply to LMIC settings
-
Cochrane review of elective term CS: ACS ↓RDS by 52% and ↓TTN by 57%, but all 4 trials at risk of bias – interpret with caution
Trial name quick-reference
ACTORDS – repeat q7d, ↓RDS/oxygen need, ↓birthweight
MACS – repeat q14d, no morbidity benefit, ↓growth, term subgroup harm at 5y
NICHD – repeat q7d (max 4), stopped early for safety/growth concerns ALPS – late preterm, ↓resp. support but ↑hypoglycaemia
ASTECS – elective term CS, ↓RDS admissions but small absolute numbers ACT – LMIC, ↑overall mortality in whole population
Abbreviation Key
- ACS — antenatal corticosteroids
- WHO — World Health Organization
- RDS — respiratory distress syndrome
- 11β-HSD2 — 11β-hydroxysteroid dehydrogenase type 2
- NEC — necrotising enterocolitis
- GR — glucocorticoid receptor
- IVH — intraventricular haemorrhage
- HPA — hypothalamic–pituitary axis
- PVL — periventricular leukomalacia
- fFN — fetal fibronectin
- BPD — bronchopulmonary dysplasia
- AUROC — area under the receiver operating characteristic curve
- TTN — transient tachypnoea of the newborn
- RCT — randomised controlled trial
- PPROM — preterm prelabour rupture of membranes
- RR — relative risk
- NICE — National Institute for Health and Care Excellence
- OR — odds ratio
- ACOG — American College of Obstetricians and Gynecologists
- HR — hazard ratio
- CI — confidence interval
- ALPS — Antenatal Late Preterm Steroids trial
- MACS — Multiple Courses of Antenatal Corticosteroids for Preterm
- ASTECS — Antenatal Steroids for Term Caesarean Section trial Birth trial
- ASTEROID — betamethasone vs dexamethasone RCT
- ACTORDS — Australasian Collaborative Trial of Repeat Doses of
- ACT — Antenatal Corticosteroids Trial (LMIC cluster RCT) Steroids
- LMIC — low- and middle-income countries
- NICHD — National Institute of Child Health and Human Development study
Source: Busuulwa P et al. The role of antenatal corticosteroids in improving neonatal outcomes. The Obstetrician & Gynaecologist 2021;23:246–257. doi:10.1111/tog.12768
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).